GLAXO ZANAMIVIR IN PHASE III TRIALS FOR INHALED USE IN INFLUENZA; COMPANY WORKING WITH PARTNERS ON FLU TEST: SEREVENT/FLOVENT COMBO FILING PLANNED FOR 1998
Glaxo Wellcome has begun Phase III trials of the inhaled neuraminidase inhibitor zanamivir for treatment of influenza, acting Head of Internal Medical Affairs Rick Fuller, MD, told a meeting of securities analysts at a company R&D update in New York City May 5.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth